Figure 7
Treg depletion by IL-2DT treatment augments CTL infiltration into sites of AML metastases. AML-bearing mice were treated with IL-2DT or control DT (1 μg/dose) 4 and 13 days after tumor injection. Congenic B6-Ly5.2 (CD45.1+) CTLs (30 × 106/dose) were then injected intravenously 14 days after tumor injection and organs were harvested 6 days after CTL infusion. Confocal microscopy was performed. Naive B6 mice were used as normal tissue controls. (A) CD4 (green) and Foxp3 (red); (B) CD45.1 (green) and DsR (red); (C) CD45.1 (green) and Foxp3 (red); and (D) CD45.1 (green) and CD31 (red). Representative data from 1 of 2 similar experiments are shown.
